Hazard Information | Back Directory | [Uses]
Treatment of anthrax infection. | [Brand name]
ABthrax (Human Genome Sciences). | [in vivo]
Raxibacumab (150 μg/kg or 300 μg/kg for i.v., single dose) significantly improved in outcome when it was administered up to 6 h after rats initial exposure to Bacillus anthracis lethal toxin (LeTx) infusion[3].
Animal Model: | In SD rats after the initiation of a 24-h LeTx infusion[3] | Dosage: | 150 μg/kg or 300 μg/kg | Administration: | At the time of or 3, 6, 9, or 12 h after the initiation of LeTx infusion, the rats were randomized to be treated i.v. in a single dose | Result: | Significantly improved in outcome when it was administered up to 6 h (and approached significance when administered up to 12 h) after initial exposure to LeTx.
Rats receiving raxibacumab within 6 hours of toxin administration had a better survival rate than those that received raxibacumab at 9 or 12 hours.
|
|
|
Company Name: |
Biolab Reagents
|
Tel: |
18108604356 18108604356 |
Website: |
www.biolabreagent.com/ |
Company Name: |
Cell Sciences
|
Tel: |
9785721070 |
Website: |
www.cellsciences.com |
Company Name: |
Wonda Science
|
Tel: |
+1 (514) 581-6866 |
Website: |
www.wondascience.com |
|